Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Oncology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Oncology Other
    Palonosetron/Dexamethasone Combination Effective in Preventing Nausea, Vomiting After Chemotherapy - (DGNews)
    FDA Approves Imatinib Mesylate to Prevent Recurrence of GI Stromal Tumour - (DGNews)
    Combining 3 Infection Control Measures Reduces Mortality in High-Risk Cancer Patients - (DGNews)
    Wide Range of Eye Conditions Reported Following Off-label Use of Bevacizumab - (DGNews)
    Long-term All-Cause Mortality in Cancer Patients With Preexisting Diabetes Mellitus: A Systematic Review and Meta-analysis - (JAMA)

    News archive

     Recent webcasts/CME - Oncology Other
  • Maximizing Outcomes in CML Throughout the Treatment Continuum
  • Long-Term Management of a Patient With Newly Diagnosed, Chronic-Phase CML
  • Choosing Appropriate Second-Line Therapy for a Patient With Progressive/Treatment-Resistant CML
  • Rheumatoid Arthritis and Malignancy: Associations, Effects of Treatment, and Discussion of Options for Patients with Prior Cancer

    Webcasts/CME archive

     Recent cases - Oncology Other
      A Case of Radiation-Induced Sternal Malignant Fibrous Histiocytoma Treated with Neoadjuvant Chemotherapy and Surgical Resection
      Advanced Gastric Cancer Showing Long Term Complete Remission in Response to S1 Monotherapy: Two Case Reports
      A Rare Case of Advanced Testicular Seminoma in a 78-Year-Old Man Managed Successfully with Carboplatin Based Chemotherapy: A Case Report
      Metastasis of Bronchogenic Carcinoma to the 5th Metacarpal Bone: A Case Report
      A Large Dumbbell Glossopharyngeal Schwannoma Involving Vagus Nerve: A Case Report and Review of Literature

      Cases archive
        




      my personal edition > oncology other > news
      divider

        E-Mail this DGReview to a colleague

      DGReview


      Camptothecin Analogues, Combined with Cyclophosphamide, Have Potential Role in Treatment of Resistant Neuroblastoma

      A DGReview of :"Camptothecin Analogs (Irinotecan or Topotecan) plus High-Dose Cyclophosphamide as Preparative Regimens for Antibody-Based Immunotherapy in Resistant Neuroblastoma"
      Clinical Cancer Research

      02/05/2004
      By Deanna M Green, PhD


      The addition of camptothecin analogues to high-dose cyclophosphamide shows modest activity and tolerable morbidity in patients with relapsed or refractory neuroblastoma, according to an American retrospective study. Furthermore, this combination may be a good preparative regimen for passive immunotherapy with monoclonal antibodies.

      Camptothecin analogues, such as topotecan and irinotecan, are highly active against resistant neuroblastoma cells in vitro and have a manageable and transient nonhaematological toxicity profile. Studies have also suggested that these agents can be safely given with other anticancer drugs. The use of camptothecin analogues, therefore, has great promise in the treatment of neuroblastoma.

      Brian H. Kushner, MD, and colleagues at the Memorial Sloan-Kettering Cancer Centre, New York, United States, evaluated the use of high-dose cyclophosphamide plus topotecan/vincristine (CTV) or irinotecan (C/I) in patients with resistant neuroblastoma.

      The study included 55 patients with relapsed or refractory neuroblastoma who had previously received topotecan, a haemopoietic stem-cell transplant, and/or high-dose cyclophosphamide.

      All patients were treated with cyclophosphamide (70 mg/kg) on days 1 and 2. Furthermore, 29 patients received topotecan (2 mg/m2) on days 1 to 4 and vincristine (0.067 mg/kg) on day 1; and 26 patients were given irinotecan (50 mg/m2) on days 1 to 5. Mensa (70 mg/kg) and granulocyte colony-stimulating factor were also used.

      Both regimens resulted in a similar prolonged duration of grade 4 myelosuppression.

      Specifically, the absolute neutrophil count was below 500 cells/µLfor 5-12 days in patients who had not received haemopoietic stem-cell transplants and for 7 to 21 days in post-transplant patients. Furthermore, platelet counts recovered above 75,000 cells/µL for 21 to 28 days and 17 to 40 days in these respective groups.

      Blood-borne bacterial infections were identified in 14.5% of patients, and led to death from septic shock in 1 case. Suspected typhlitis occurred in 5.5% of patients. Two other patients showed clinical signs of sepsis and pneumonia, respectively.

      One CTV-treated patient had grade 3 generalised pain attributable to vincristine, and 1 C/I-treated patient developed haemorrhagic cystitis. All other toxicities were grade 2 or lower, including 3 cases of grade 2 mucositis that only occurred in CTV-treated patients.

      Overall, 15% of CTV-treated patients and 17% of C/I-treated patients with assessable disease achieved a partial response or better. Moreover, bone marrow disease resolved in 28% and 27%, respectively.

      Furthermore, passive immunotherapy with the murine anti-GD2 monoclonal antibody 3F8 was possible after chemotherapy in 45% of CTV-treated patients and in 27% of C/I-treated patients. These patients did not develop persistent human anti-mouse antibody, consistent with the desired immunosuppressive effect of high-dose cyclophosphamide.

      The authors conclude that "CTV and C/I have modest anti-neuroblastoma activity in heavily treated patients, immunomodulatory effects conducive to antibody-mediated immunotherapy, and modest toxicity to major nonhaematological organs."

      Clin Cancer Res 2004 Jan 1;10:1:84-7. "Camptothecin Analogs (Irinotecan or Topotecan) plus High-Dose Cyclophosphamide as Preparative Regimens for Antibody-Based Immunotherapy in Resistant Neuroblastoma"

      E-Mail this DGReview to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send